NRXS - Earnings announcements

CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025. 4Q25 Financial Highlights Revenues increased 27% year over year to $968 thousand in 4Q25.Operating loss increased 17% year over year, primarily due to higher selling expenses directly related to increased sales volume and compensation expenses to facilitate growth.  Cash balance was $5.0 million as of December 31, 2025. FY2025 Financial Highlights

CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2025, for the period ended December 31, 2025, on Thursday, March 19, 2026, before market open. The Company has scheduled a conference call for the same day, Thursday, March 19, 2026, at 9:00 am ET to review the results. Conference Call Details Date and Time: Thursday, March 19, 2026, at 9:00am ET Live Webcast Information: Interested parties can access the confere

CARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its third quarter 2025, for the period ended September 30, 2025, on Tuesday, November 11, 2025, before market open. The Company has scheduled a conference call for the same day, Tuesday, November 11, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, November 11, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live we

CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter 2025 for the period ended June 30, 2025. 2Q25 Financial highlights Revenues increased 46% year over year to $894 thousand in 2Q25 compared to $612 thousand in 2Q24.Operating expenses decreased 10% year over year in 2Q25 compared to 2Q24.Operating loss improved by 22% compared to the second quarter of 2024.Cash balance was $6 million as of June 30, 2025. The Company secured $5 million through an equity-on

CARMEL, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its second quarter 2025, for the period ended June 30, 2025, on Tuesday, August 12, 2025, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 12, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, August 12, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webcast, whi

CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025. 1Q25 Financial highlights Revenues increased 39% year over year to $896 thousand in 1Q25 compared to $647 thousand in 1Q24.Revenues increased 18% quarter over quarter to $896 thousand in 1Q25 compared to $761 thousand in 4Q24.Operating loss (excluding a one-time legal settlement) improved by 9% compared to the first quarter of 2024.Cash balance was $2.0 million as

CARMEL, Ind., May 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its first quarter 2025, for the period ended March 31, 2025, on Monday, May 12, 2025, before market open. The Company has scheduled a conference call for the same day, Monday, May 12, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Monday, May 12, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webcast, which is availab

CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2024 for the period ended December 31, 2024. 4Q24 Financial highlights Revenues increased 43% to $761 thousand in 4Q24 compared to $531 thousand in 4Q23.Operating loss improved by 10% compared to the fourth quarter of 2023.Cash balance was $3.7 million as of December 31, 2024. Recent Operational Highlights Expanded total covered lives to approximately 51 million compared to 4 million a

CARMEL, Ind., March 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2024, for the period ended December 31, 2024, on Thursday, March 20, 2025, before market open. The Company has scheduled a conference call for the same day, Thursday, March 20, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Thursday, March 20, 2025, at 9:00am ET Live Webcast Information: Interested parties can access the confere

CARMEL, Ind., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its third quarter period ended September 30, 2024, on Tuesday, November 12, 2024, before market open. The Company has scheduled a conference call for the same day, Tuesday, November 12, 2024, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, November 12, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webca

Carmel, Ind., Aug. 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter period ended June 30, 2024. Recent Operational Highlights Expanded total covered lives to approximately 22.5 million covered lives compared to 4.5 million covered lives as of May 1, 2023. Recent medical policy coverages include: BCBS licensee in Florida covering over 6 million lives.BCBS licensee in North Dakota covering over 310,000 people.BCBS plan in the mid-Atlantic region, providing coverage fo

CARMEL, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2024, on Friday, August 9, 2024, before market open. The Company has scheduled a conference call for the same day, Friday, August 9, 2024, at 9:00 am ET to review the results. Conference Call Details Date and Time: Friday, August 9, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webcast, wh

CARMEL, Ind., May 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2024 for the period ended March 31, 2024. Recent Operational Highlights Expanded total covered lives to approximately 22.5 million covered lives, an increase of 400% compared to 4.5 million covered lives as of May 1, 2023. Recent medical policy coverages include: BCBS licensee in Florida covering over 6 million lives.BCBS licensee in North Dakota covering over 310,000 people.BCBS plan in the mid-Atlantic r

CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its first quarter 2024, for the period ended March 31, 2024, on Wednesday, May 22, 2024, before market open. The Company has scheduled a conference call for the same day, Wednesday, May 22, 2024, at 9:00 am ET to review the results. Filing of 10-QFollowing today's filing of a Form 12b-25 with the SEC, the Company expects to file its Form 10-Q on Monday, May 20, 2024. Conference Call Details Date and

CARMEL, Ind., April 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2023 for the period ended December 31, 2023. Recent Operational Highlights Expanded total covered lives to approximately 16 million individuals, an increase of 300% compared to 4 million individuals as of April 1, 2023. Recent medical policy coverages include: BCBS plan in the mid-Atlantic region, providing coverage for approximately 7 million covered lives.Coverage from a major insurer

CARMEL, Ind., April 01, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its fourth quarter and fiscal year 2023, for the period ended December 31, 2023, on Tuesday, April 9, 2024, after the close of the market. The Company has scheduled a conference call for the same day, Tuesday, April 9, 2024, at 4:30 pm ET to review the results. Conference Call Details Date and Time: Tuesday, April 9, 2024, at 4:30pm ET Live Webcast Information: Interested parties can access the conference ca